Nuvalent, Inc. Class A NUVL 深 沪
等待开盘 06-24 09:30:00 美东时间
123.44
+0.020
+0.02%
华盛通- 最 高123.52
- 今 开123.49
- 成交量 133.59万股
- 最 低 123.41
- 昨 收 123.42
- 总市值 596.39万
- 52周最高 123.62
- 市盈率 静 --
- 换手率 2765.05%
- 52周最低 71.14
- 委 比 0.00%
- 总股本 4.83万
- 历史最高 123.62
- 量 比 0.37
- 振 幅 0.09%
- 历史最低 1.10
- 每 手 1
- 风险率 12.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Crude Oil Falls Over 5%; US Trade Gap Narrows In April
US stocks down, Dow Jones drops 300 points. Real estate shares up, technology stocks down. U.S. trade deficit shrinks, imports and exports increase.
06-10 00:30
Cantor Fitzgerald Downgrades Nuvalent to Neutral
Cantor Fitzgerald analyst Josh Schimmer downgrades Nuvalent (NASDAQ:NUVL) from Overweight to Neutral.
06-09 22:06
Nuvalent Announces $500M Class A Common Stock Offering
Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that it has commenced an
2025-11-18 05:02
Why Nuvalent (NUVL) Shares Are Down 6% Today
Nuvalent shares are trading lower by 6.2% during Tuesday's session. The company priced a $500 million public offering of 5 million shares at $100 each.
2024-09-18 02:37
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite fall...
2024-09-17 00:31
Alcoa, Lattice Semiconductor, Stratasys And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed, with the Dow Jones index gaining around 200 points on M...
2024-09-16 22:03
Wedbush Reiterates Outperform on Nuvalent, Maintains $99 Price Target
Wedbush analyst David Nierengarten reiterates Nuvalent (NASDAQ:NUVL) with a Outperform and maintains $99 price target.
2024-09-09 20:37
Nuvalent to Present Cancer Therapy Data at ESMO 2024, Highlighting Key Trials
Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced data from
2024-09-09 18:31
JP Morgan Maintains Overweight on Nuvalent, Raises Price Target to $100
JP Morgan analyst Anupam Rama maintains Nuvalent (NASDAQ:NUVL) with a Overweight and raises the price target from $90 to $100.
2024-09-05 06:14
